2nd Distributor in Canada, Entire $75m Market Now Covered
| Stock | Orthocell Ltd (OCC.ASX) |
|---|---|
| Release Time | 5 Nov 2025, 8:59 a.m. |
| Price Sensitive | Yes |
Orthocell Appoints Second Canadian Distributor for Remplir
- Full national coverage of US$75m Canadian market now in place
- New Ontario-based distributor granted exclusive rights for 8 provinces
- First Canadian sales expected this Quarter following successful launch activities
Orthocell Limited (ASX: OCC) has announced the appointment of its second Canadian distributor for Remplir, the Company's flagship nerve repair medical device. The appointment complements the existing Canadian distributor already in place, ensuring the Company now has full national coverage in the US$75 million Canadian market. The new Ontario-based distributor, who brings a wealth of expertise in nerve, spine, and orthopaedic implant distribution, has been granted exclusive distribution rights for Remplir for the provinces of Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland. With the existing Canadian distributor covering the remaining Alberta and British Columbia, Remplir is now available to patients in both rural and urban healthcare facilities across Canada. The distribution team includes 6 product managers driving a team of 30 sales agents. Orthocell completed initial launch activities for Remplir in Canada at the prestigious Annual Meeting of the American Society for Surgery of the Hand, held in Vancouver in October and expects first sales to be delivered this Quarter. Future launch activities and commercialisation efforts in Canada will be managed by Orthocell's existing US-based Marketing and Medical Education teams, thereby bringing significant efficiencies to the Company's North American rollout.
Orthocell received a Medical Device Licence (MDL) from Health Canada for its flagship nerve repair product Remplir in April 2025, well ahead of initial expectations. With more than $50 million in cash and no debt, Orthocell is well-positioned to drive rapid product adoption to deliver a step change in revenue in FY26.
Remplir rollout in the US$1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts. Initial US surgical cases continue to build.